Literature DB >> 27091426

Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels.

An T Phan1, Samantha G Fernandez1, Jessica J Somberg1, Kristin M Keck1, Jj L Miranda2.   

Abstract

The human Epstein-Barr virus (EBV) evades the immune system by entering a transcriptionally latent phase in B cells. EBV in tumor cells expresses distinct patterns of genes referred to as latency types. Viruses in tumor cells also display varying levels of lytic transcription resulting from spontaneous reactivation out of latency. We measured this dynamic range of lytic transcription with RNA deep sequencing and observed no correlation with EBV latency types among genetically different viruses, but type I cell lines reveal more spontaneous reactivation than isogenic type III cultures. We further determined that latency type and spontaneous reactivation levels predict the relative amount of induced reactivation generated by cytotoxic chemotherapy drugs. Our work has potential implications for personalizing medicine against EBV-transformed malignancies. Identifying latency type or measuring spontaneous reactivation may provide predictive power in treatment contexts where viral production should be either avoided or coerced.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epstein–Barr virus; Latency; RNA-seq; Reactivation; Transcriptome

Mesh:

Substances:

Year:  2016        PMID: 27091426      PMCID: PMC4860101          DOI: 10.1016/j.bbrc.2016.04.070

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

1.  Bendamustine reactivates latent Epstein-Barr virus.

Authors:  Samantha G Fernandez; J J L Miranda
Journal:  Leuk Lymphoma       Date:  2015-09-15

2.  Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry.

Authors:  B M Imbert-Marcille; M Coste-Burel; N Robillard; J Foucaud-Gamen; S Billaudel; E Drouet
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

3.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

4.  Selective transformation of B lymphocytes by E.B. virus.

Authors:  P K Pattengale; R W Smith; P Gerber
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

5.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

Review 6.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

Review 7.  Epstein-Barr virus and oncogenesis: from latent genes to tumours.

Authors:  Lawrence S Young; Paul G Murray
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

Review 8.  Virally targeted therapies for EBV-associated malignancies.

Authors:  Bruce F Israel; Shannon C Kenney
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

9.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.

Authors:  Gemma Kelly; Andrew Bell; Alan Rickinson
Journal:  Nat Med       Date:  2002-09-03       Impact factor: 53.440

View more
  9 in total

1.  The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.

Authors:  Kristen D Yetming; Lena N Lupey-Green; Sergei Biryukov; David J Hughes; Elessa M Marendy; Jj L Miranda; Jeffery T Sample
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  The immunogenetics of viral antigen response is associated with subtype-specific glioma risk and survival.

Authors:  Geno Guerra; Linda Kachuri; George Wendt; Helen M Hansen; Steven J Mack; Annette M Molinaro; Terri Rice; Paige Bracci; John K Wiencke; Nori Kasahara; Jeanette E Eckel-Passow; Robert B Jenkins; Margaret Wrensch; Stephen S Francis
Journal:  Am J Hum Genet       Date:  2022-05-11       Impact factor: 11.043

3.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

4.  The Epstein-Barr Virus Episome Maneuvers between Nuclear Chromatin Compartments during Reactivation.

Authors:  Stephanie A Moquin; Sean Thomas; Sean Whalen; Alix Warburton; Samantha G Fernandez; Alison A McBride; Katherine S Pollard; Jj L Miranda
Journal:  J Virol       Date:  2018-01-17       Impact factor: 5.103

5.  PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.

Authors:  Lena N Lupey-Green; Stephanie A Moquin; Kayla A Martin; Shane M McDevitt; Michael Hulse; Lisa B Caruso; Richard T Pomerantz; Jj L Miranda; Italo Tempera
Journal:  Virology       Date:  2017-04-26       Impact factor: 3.616

6.  Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps.

Authors:  Kristin M Keck; Stephanie A Moquin; Amanda He; Samantha G Fernandez; Jessica J Somberg; Stephanie M Liu; Delsy M Martinez; Jj L Miranda
Journal:  J Biol Chem       Date:  2017-06-06       Impact factor: 5.157

7.  Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas.

Authors:  Octavia Ramayanti; Mitch Brinkkemper; Sandra A W M Verkuijlen; Leni Ritmaleni; Mei Lin Go; Jaap M Middeldorp
Journal:  Cancers (Basel)       Date:  2018-03-22       Impact factor: 6.639

8.  RNA-seq detects pharmacological inhibition of Epstein-Barr virus late transcription during spontaneous reactivation.

Authors:  An T Phan; Delsy M Martinez; Jj L Miranda
Journal:  Genom Data       Date:  2017-05-12

9.  Rationally repurposed nitroxoline inhibits preclinical models of Epstein-Barr virus-associated lymphoproliferation.

Authors:  Maite Ibáñez de Garayo; Wendi Liu; Nicole C Rondeau; Christopher B Damoci; J J L Miranda
Journal:  J Antibiot (Tokyo)       Date:  2021-06-23       Impact factor: 2.649

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.